Safety-Related Regulatory Actions for Orphan Drugs in the US and EU

Timing of New Black Box Warnings and Withdrawals for Prescription Medications

Karen E. Lasser · JAMA · 2002 · 1K citations

Pharmacy, Pharmacology, Clinical Pharmacology +16

Cardiac Rehabilitation and Survival in Older Coronary Patients

Jose A. Suaya, William B. Stason, Philip A. Ades et al. · Journal of the American College of Cardiology · 2009 · 552 citations

Medicine, Cardiology, Geriatric Medicine +14

Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors

Martin H. Cohen, Ann T. Farrell, Robert Justice et al. · The Oncologist · 2009 · 429 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union

Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Sabine M. J. M. Straus et al. · JAMA · 2008 · 268 citations

Pharmacy, Pharmaceutical Policy, Immunization +16

Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products

James W. Dear, Pajaree Lilitkarntakul, David J. Webb · British Journal of Clinical Pharmacology · 2006 · 88 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +17